Last reviewed · How we verify
Qsymia
At a glance
| Generic name | Qsymia |
|---|---|
| Also known as | VI-0521, Phentermine and Topiramate ER (Extended Release) |
| Sponsor | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Preoperative Weight Loss for Open Abdominal Wall Reconstruction (NA)
- Individualized Pharmacological Approach to Obesity in Patients With Bipolar Disorder (PHASE4)
- Pharmacotherapy in Conjunction With Lifestyle Counseling for Management of Weight Regain After Bariatric Surgery (PHASE4)
- Weight Gain Prevention in Adolescents and Young Adults (PHASE3)
- Phentermine/Topiramate for Uric Acid Stones (PHASE3)
- A Research Study Comparing Wegovy to Other Weight Management Drugs in People Living With Obesity in America (PHASE4)
- Sequential or CombinaTion Anti-obesitY Medication With Muscle Preservation for Weight Loss and MaintEnance: A PragmAtic Randomized CoNtrolled Trial (STAY-LEAN Trial) (PHASE4)
- Phentermine/Topiramate in Adolescents With Type 2 Diabetes and Obesity (EARLY_PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Qsymia CI brief — competitive landscape report
- Qsymia updates RSS · CI watch RSS
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) portfolio CI